Alimentary Pharmacology & Therapeutics

the management of pouchitis
pp. 449-457(9)
Author: Keighley, M.R.B.

safety of bismuth in the treatment of gastrointestinal diseases
pp. 459-467(9)
Authors: Tillman, L.A.; Drake, F.M.; Dixon, J.S.; Wood, J.R.

clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease
pp. 469-486(18)
Author: Penston, J.G.

older systemic and newer topical glucocorticosteroids and the gastrointestinal tract
pp. 487-496(10)
Authors: Thiesen, A.; Thomson, A.B.R.

Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15mmol/h
pp. 497-506(10)
Authors: Hirschowitz, B.I.; Mohnen, J.; Shaw, S.

Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome
pp. 507-522(16)
Authors: Hirschowitz, B.I.; Mohnen, J.; Shaw, S.

Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects
pp. 523-2813(2291)
Authors: Fraser, A.G.; Sawyerr, A.M.; Hudson, M.; Smith, M.S.H.; Pounder, R.E.

Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis
pp. 529-539(11)
Authors: Gough, A.L.; Long, R.G.; Cooper, B.T.; Foster, C.S.; Garrett, A.D.; Langworthy, C.H.

Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin
pp. 541-545(5)
Authors: Schenk, B.E.; Festen, H.P.M.; Kuipers, E.J.; Klinkenberg-Knol, E.C.; Meuwissen, S.G.M.

Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis
pp. 547-555(9)
Authors: Bate, C.M.; Griffin, S.M.; Keeling, P.W.N.; Axon, A.T.R.; Dronfield, M.W.; Chapman, R.W.G.; O'donoghue, D.; Calam, J.; Crowe, J.; Mountford, R.A.; Watts, D.A.; Taylor, M.D.; Richardson, P.D.I.

Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole
pp. 557-561(5)
Authors: Lewis, S.J.; Franco, S.; Young, G.; O'keefe, S.J.D.

Effects of misoprostol on healing and prevention of biopsy-induced gastroduodenal lesions occurring during the administration of diclofenac to volunteers
pp. 563-569(7)
Authors: Dorta, G.; Nicolet, M.; Vouillamoz, D.; Margalith, D.; Blum, A.L.; Armstrong, D.

Omeprazole prevents indomethacin-induced gastric ulcers in rabbits
pp. 571-576(6)
Authors: Lee, M.; Kallal, S.M.; Feldman, M.

Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumours
pp. 577-586(10)
Authors: Azcona, C.; Castro, L.; Crespo, E.; Jimenez, M.; Sierrasesumaga, L.

Factors affecting dose selection and outcome of cisapride treatment for dyspepsia in primary care
pp. 587-594(8)
Author: Brunner, H.

Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
pp. 595-599(5)
Authors: Maxton, D.G.; Morris, J.; Whorwell, P.J.

Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation
pp. 601-605(5)
Authors: Gionchetti, P.; Campieri, M.; Venturi, A.; Rizzello, F.; Ferretti, M.; Brignola, C.; Miglioli, M.

Antral gastrin cell hyperfunction and Helicobacter pylori infection
pp. 607-615(9)
Authors: Annibale, B.; Rindi, G.; D'ambra, G.; Marignani, M.; Solcia, E.; Bordi, C.; delle Fave, G.

One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection
pp. 617-621(5)
Authors: Yousfi, M.M.; El-Zimaity, H.M.T.; Genta, R.M.; Graham, D.Y.

The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori
pp. 623-630(8)
Authors: Wyeth, J.W.; Pounder, R.E.; Duggan, A.E.; O'morain, C.A.; Schaufelberger, H.D.; de Koster, E.H.; Rauws, E.A.J.; Bardhan, K.D.; Gilvarry, J.; Buckley, M.J.M.; Gummett, P.A.; Logan, R.P.H.

Enhanced eradication of Helicobacter pylori by pre- versus post-prandial amoxycillin suspension with omeprazole: implications for antibiotic delivery
pp. 631-635(5)
Authors: Atherton, J.C.; Cullen, D.J.E.; Kirk, G.E.; Hawkey, C.J.; Spiller, R.C.

Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole
pp. 637-644(8)
Authors: Bell, G.D.; Bate, C.M.; Axon, A.T.R.; Tildesley, G.; Martin, J.L.; Taylor, M.D.; Richardson, P.D.I.

Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy
pp. 645-650(6)
Authors: Lai, J.Y.L.; de Boer, W.A.; Driessen, W.M.M.; Geuskens, L.M.

Bile acid therapy versus placebo before and after extracorporeal shock wave lithotripsy of gallbladder stones
pp. 651-657(7)
Authors: The East-Danish Gallstone Study Group,; Matzen, P.

Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome
pp. 659-663(5)
Authors: Tebano, M.T.; Traversa, G.; Da Cas, R.; Loizzo, A.

Essential fatty acid supplementation in chronic hepatitis B
pp. 665-668(4)
Authors: Jenkins, A.P.; Green, A.T.; Thompson, R.P.H.